Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil
暂无分享,去创建一个
A. Fabro | C. Ferreira | D. Carraro | F. Soares | Isabela Werneck da Cunha | V. Capelozzi | A. C. de Melo | E. Olivieri | C. Sternberg | T. Takagaki | M. J. De Barros E. Silva | Vanessa Karen de Sá | Haynna Kimie Pimenta Inada | E. S. de Mello | M. J. de Barros E Silva | Milton José de Barros e Silva
[1] C. Kang,et al. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[2] Changli Wang,et al. Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer , 2014, PloS one.
[3] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[4] Quan Zhang,et al. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status , 2014, Journal of Cancer Research and Clinical Oncology.
[5] T. Chou,et al. Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma , 2013, Annals of surgery.
[6] Wei Wu,et al. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients , 2013, Medical Oncology.
[7] M. Jin,et al. Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues , 2013, PloS one.
[8] P. Russell,et al. Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] Y. Li,et al. Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer , 2013, PloS one.
[10] A. Yoshizawa,et al. Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] M. Varella‐Garcia,et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer , 2012, Cancer.
[12] Shuhang Wang,et al. EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer , 2012, Oncology.
[13] C. Bacchi,et al. Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population , 2012, Clinics.
[14] E. Ojopi,et al. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients , 2012, Clinics.
[15] W. Pao,et al. Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis , 2012, Clinical Cancer Research.
[16] H. Lee,et al. High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] Yih-Leong Chang,et al. EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] R. Rosell,et al. Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] H. Shim,et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. , 2011, Archives of pathology & laboratory medicine.
[20] Masahiro Tsuboi,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] S. Dacic,et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010, Modern Pathology.
[22] M. Loda,et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. , 2009, Cancer research.
[23] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Li Li,et al. Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers , 2009, Molecular Cancer Research.
[25] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[26] M. Nikiforova,et al. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. , 2009, American journal of clinical pathology.
[27] E. Campo,et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.
[28] Y. Ishikawa,et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. , 2009, Lung cancer.
[29] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[30] W. Gerald,et al. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.
[31] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] J. Crowley,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] P. Nederlof,et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[35] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[36] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[37] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Ferlay,et al. Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.
[39] G. Capellá,et al. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. , 1991, Environmental health perspectives.
[40] Liquid Biopsies. Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.
[41] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[42] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[43] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[44] Liu Yan-hui,et al. Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .
[45] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[46] H. Hansen,et al. Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[47] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.